AstraZeneca, Daiichi Sankyo Seek Regulatory Approvals for Enhertu in Early Breast Cancer
Mar 10, 2026
The US FDA granted priority review and the European Medicines Agency validated applications for Enhertu as post-neoadjuvant treatment for HER2-positive early breast cancer, based on Phase III trial data showing 53% reduction in recurrence risk.